Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...
Research Square
Katelyn Halpape, Raelle Pashovitz, Annabelle Wanson et al.
preprint
Abstract Background Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as...
Michael Alvear
preprint
This report summarizes more than 25 systematic reviews and meta-analyses published between 2020 and 2025 on ketamine-based therapies for depression. It provides a comparative analysis of intravenous (IV) ketamine, esketamine nasal spray (Spravato), and oral ketamine, highlighting differences in response rates, remission rates, speed of symptom relief, and durability of results.It also examines...
Minna Chang
Ketamine has been shown to be a novel and exciting antidepressant medication in patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage, seen in over 25% of regular users (3, 4). Although KIC is a recognised...
Research Square
Minna Chang
preprint
Abstract Ketamine has been shown to be a novel and exciting antidepressant medication in patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage, seen in over 25% of regular users (3, 4). Although KIC is a recognised...